Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer

Pruthi, Sandhya; Gostout, Bobbie S.; Lindor, Noralane M.
December 2010
Mayo Clinic Proceedings;Dec2010, Vol. 85 Issue 12, p1111
Academic Journal
Women with a germline BRCA1 or BRCA2 mutation or a hereditary predisposition for breast and ovarian cancer have substantial risk of breast or ovarian cancer relative to the general US population. Health care professionals can be instrumental in identifying women at increased risk through obtaining a comprehensive family history and becoming familiar with family history characteristics associated with hereditary predisposition for breast and ovarian cancer. BRCA carriers and women at very high risk benefit from multidisciplinary, individualized medical evaluation and risk management. We conducted a search of MEDLINE from 1989 through 2010 for the terms BRCA1, BRCA2, breast cancer, ovarian cancer, risk assessment, and genetic testing. We reviewed abstracts and relevant randomized and prospective studies that included very high-risk patient groups and BRCA mutation carriers. Herein, we review the role of genetic consultation and BRCA testing and the comprehensive, multisystem recommendations for risk management. A multidisciplinary approach offers the ability to educate those at very high risk about cancer prevention, reduce cancer risk, maximize early detection of breast and ovarian cancer, and improve survival.


Related Articles

  • BRCA testing for familial breast cancer. Chiyan Lau; Suthers, Graeme // Australian Prescriber;Apr2011, Vol. 34 Issue 2, p49 

    Mutations in the BRCA1 and BRCA2 genes are associated with hereditary breast and ovarian cancer. Genetic testing is available in specialised laboratories, but is expensive and presents a significant technical and interpretative challenge. Identification of a causative mutation carries lifelong...

  • Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. Osorio, A.; Milne, R. L.; Alonso, R.; Pita, G.; Peterlongo, P.; Teulé, A.; Nathanson, K. L.; Domchek, S. M.; Rebbeck, T.; Lasa, A.; Konstantopoulou, I.; Hogervorst, F. B.; Verhoef, S.; van Dooren, M. F.; Jager, A.; Ausems, M. G. E. M.; Aalfs, C. M.; van Asperen, C. J.; Vreeswijk, M.; Waisfisz, Q. // British Journal of Cancer;4/12/2011, Vol. 104 Issue 8, p1356 

    Background: Single-nucleotide polymorphisms (SNPs) in genes involved in DNA repair are good candidates to be tested as phenotypic modifiers for carriers of mutations in the high-risk susceptibility genes BRCA1 and BRCA2. The base excision repair (BER) pathway could be particularly...

  • Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling. Meyer, Stefan; Tischkowitz, Marc; Chandler, Kate; Gillespie, Alan; Birch, Jillian M.; Evans, D. Gareth // Journal of Medical Genetics;Feb2014, Vol. 51 Issue 2, p71 

    Fanconi anaemia (FA) is an inherited condition characterised by congenital and developmental abnormalities and a strong cancer predisposition. In around 3-5% of cases FA is caused by biallelic mutations in the BRCA2 gene. Individuals heterozygous for BRCA2 mutations have an increased risk of...

  • Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Brohet, Richard M.; Velthuizen, Maria E.; Hogervorst, Frans B. L.; Meijers-Heijboer, Hanne E. J.; Seynaeve, Caroline; Collée, Margriet J.; Verhoef, Senno; Ausems, Margreet G. E. M.; Hoogerbrugge, Nicoline; van Asperen, Christi J.; García, Encarna Gómez; Menko, Fred; Oosterwijk, Jan C.; Devilee, Peter; van't Veer, Laura J.; van Leeuwen, Flora E.; Easton, Douglas F.; Rookus, Matti A.; Antoniou, Antonis C.; Resource, HEBON // Journal of Medical Genetics;Feb2014, Vol. 51 Issue 2, p98 

    Background BRCA1 or BRCA2 mutations confer increased risks of breast and ovarian cancer, but risks have been found to vary across studies and populations. Methods We ascertained pedigree data of 582 BRCA1 and 176 BRCA2 families and studied the variation in breast and ovarian cancer risks using a...

  • Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. Sidon, L; Ingham, S; Clancy, T; Clayton, R; Clarke, A; Jones, E A; Lalloo, F; Evans, D G R // British Journal of Cancer;2/14/2012, Vol. 106 Issue 4, p775 

    Background:Bilateral risk-reducing salpingo-oophorectomy (BRRSO) is the only effective way of reducing mortality from ovarian cancer. This study investigates uptake of BRRSO in 700 BRCA1/2 mutation carriers from Greater Manchester.Methods:Dates of last follow-up and BRRSO were obtained, and the...

  • Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families. Rudnicka, Helena; Debniak, Tadeusz; Cybulski, Cezary; Huzarski, Tomasz; Gronwald, Jacek; Lubinski, Jan; Gorski, Bohdan // Molecular Biology Reports;Dec2013, Vol. 40 Issue 12, p6619 

    BRCA1 and BRCA2 are two major genes associated with familial breast and ovarian cancer susceptibility. In Poland standard BRCA gene test is usually limited to Polish founder BRCA1 mutations: 5382insC, C61G and 4153delA. To date, just a few single large genomic rearrangements (LGRs) of BRCA1 gene...

  • BRCA1/BRCA2 Germline Mutations and Breast Cancer Risk. Devilee, Peter // Encyclopedic Reference of Cancer;2001, p134 

    An encyclopedia entry for "BRCA1 and BRCA2 germline mutations and breast cancer risk" is presented. Mutations in the BRCA genes causes elevated risks to breast and ovarian cancer. The mutations of the genes may result to premature termination of protein translation which is presumed to result in...

  • BRCA 1 and BRCA 2. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p123 

    An encyclopedia entry for "BRCA 1 and BRCA 2" is presented. It refers to two of the abnormal genes that are speculated to be responsible for inherited breast cancer. Women with BRCA 1 and BRCA 2 genes may experience an increased risk of ovarian cancer.

  • Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women. Noval, Begoña // Archives of Gynecology & Obstetrics;Nov2016, Vol. 294 Issue 5, p1099 

    Purpose: Women who carry a mutation in the BRCA1 or BRCA2 genes not only have an increased lifetime risk of developing breast and ovarian cancer, but also a complicated reproductive future. Based on the hypothesis that BRCA germline mutations (BRCAm) are associated with accelerated follicular...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics